[Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan].

Hideyuki Ikematsu, Yong Chong, Kenjiro Shirane, Hidehiro Toh, Hiroyuki Sasaki, Yui Koga, Michiyo Urata, Taeko Hotta, Takeshi Uchiumi, Donchon Kang
{"title":"[Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan].","authors":"Hideyuki Ikematsu,&nbsp;Yong Chong,&nbsp;Kenjiro Shirane,&nbsp;Hidehiro Toh,&nbsp;Hiroyuki Sasaki,&nbsp;Yui Koga,&nbsp;Michiyo Urata,&nbsp;Taeko Hotta,&nbsp;Takeshi Uchiumi,&nbsp;Donchon Kang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility.</p><p><strong>Methods: </strong>For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing.</p><p><strong>Results: </strong>One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA.</p><p><strong>Conclusion: </strong>No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"106 1","pages":"16-22"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fukuoka igaku zasshi = Hukuoka acta medica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility.

Methods: For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing.

Results: One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA.

Conclusion: No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[日本2011/12和2012/13流感患者流感A/H3N2神经氨酸酶基因分析]。
背景:流感病毒具有神经氨酸酶(NA),这是一种具有酶活性的表面蛋白,对病毒复制至关重要。突变可能影响用于治疗流感患者的NA抑制剂的有效性。在这项研究中,我们从流感患者的临床分离株中测定NA基因序列,以研究时间顺序的遗传变化及其与药物敏感性的关系。方法:测定96株A/H3N2病毒分离株(2011-12和12-13流感季节各48株)的50%抑制浓度(IC50)。将提取的病毒RNA进行RT-PCR,然后进行核苷酸测序。结果:在96个被测试的分离物中,有5个在NA活性相关的引物中发现了一个假定的氨基酸突变D151N。突变对IC50值没有影响。387和400个氨基酸位置的突变与IC50值增加有统计学相关性,但变化小于10倍,提示临床疗效无显著差异。少数分离株在NA的T和/或B细胞表位区发生突变。结论:未发现影响NAIs IC50值及疗效的突变。NA抗原突变对流行菌株选择的影响尚未确定。为了进一步阐明NA的遗传特征,需要进行持续的观察。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Sphingolipidosis]. Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report. Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report. Bone and Joint Diseases in Present and Future. Natural Immunity and Ocular Inflammation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1